Update in Childhood Chronic Myeloid Leukemia
Abstract
:1. Introduction
2. Are the Biologic and Clinical Features of CML the Same in Adults and Children?
3. Can the Prognostic Scores Used in Adults with CML Be Applied to Children?
4. Which of the TKIs Are Available for Children with CML?
5. What Is the Treatment of Choice for Pediatric Patients with CP-CML?
6. What Are the Effective and Optimal Doses of TKIs in Children and Adolescents with CP-CML?
7. What Are the Potential Side Effects of TKIs on Children?
8. Could TKIs Be Safely Discontinued in Responding Children and Adolescents with CML?
9. How Should Pediatric CML Patients Resistant or Intolerant to TKIs Be Managed?
10. What Is the Role of Allogeneic HSCT in Pediatric CP-CML in the TKI Era?
11. How Can the Advanced Phases Be Treated?
12. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Howlader, N.; Noone, A.M.; Krapcho, M.; Miller, D.; Brest, A.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.R.; et al. SEER Cancer Statistics Review, 1975–2017; National Cancer Institute: Bethesda, MD, USA, 2020.
- Andolina, J.R.; Neudorf, S.M.; Corey, S.J. How I treat childhood CML. Blood 2012, 119, 1821–1830. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Millot, F.; Baruchel, A.; Guilhot, J.; Petit, A.; Leblanc, T.; Bertrand, Y.; Mazingue, F.; Lutz, P.; Vérité, C.; Berthou, C.; et al. Imatinib Is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J. Clin. Oncol. 2011, 29, 2827–2832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Champagne, M.A.; Fu, C.H.; Chang, M.; Chen, H.; Gerbing, R.B.; Alonzo, T.A.; Cooley, L.; Heerema, N.A.; Oehler, V.; Wood, C.; et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children’s Oncology Group. Pediatr. Blood Cancer 2011, 57, 56–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giona, F.; Putti, M.C.; Micalizzi, C.; Menna, G.; Moleti, M.L.; Santoro, N.; Iaria, G.; Ladogana, S.; Burnelli, R.; Consarino, C.; et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: The Italian experience. Br. J. Haematol. 2015, 170, 398–407. [Google Scholar] [CrossRef]
- Suttorp, M.; Schulze, P.; Glauche, I.; Göhring, G.; von Neuhoff, N.; Metzler, M.; Sedlacek, P.; de Bont, E.S.J.M.; Balduzzi, A.; Lausen, B.; et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial. Leukemia 2018, 32, 1657–1669. [Google Scholar] [CrossRef]
- Shima, H.; Tokuyama, M.; Tanizawa, A.; Tono, C.; Hamamoto, K.; Muramatsu, H.; Watanabe, A.; Hotta, N.; Ito, M.; Kurosawa, H.; et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J. Pediatr. 2011, 159, 676–681. [Google Scholar] [CrossRef]
- Bansal, D.; Shava, U.; Varma, N.; Trehan, A.; Marwaha, R.K. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr. Blood Cancer 2012, 59, 481–484. [Google Scholar] [CrossRef]
- Giona, F.; Mariani, S.; Gnessi, L.; Moleti, M.L.; Rea, M.; De Vellis, A.; Marzella, D.; Testi, A.M.; Foà, R. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica 2013, 98, e25. [Google Scholar] [CrossRef]
- Millot, F.; Guilhot, J.; Baruchel, A.; Petit, A.; Leblanc, T.; Bertrand, Y.; Mazingue, F.; Lutz, P.; Vérité, C.; Berthou, C.; et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur. J. Cancer 2014, 50, 3206–3211. [Google Scholar] [CrossRef]
- Samis, J.; Lee, P.; Zimmerman, D.; Arceci, R.J.; Suttorp, M.; Hijiya, N. Recognizing endo- crinopathies associated with tyrosine kinase inhibitor therapy in children with chronic my- elogenous leukemia. Pediatr. Blood Cancer 2016, 63, 1332–1338. [Google Scholar] [CrossRef]
- Gore, L.; Kearns, P.R.; de Martino, M.L.; De Souza, C.A.; Bertrand, Y.; Hijiya, N.; Stork, L.C.; Chung, N.G.; Cardos, R.C.; Saikia, T.; et al. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J. Clin. Oncol. 2018, 36, 1330–1338. [Google Scholar] [CrossRef] [PubMed]
- Hijiya, N.; Maschan, A.; Rizzari, C.; Shimada, H.; Dufour, C.; Goto, H.; Kang, H.J.; Guinipero, T.; Karakas, Z.; Bautista, F.; et al. A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety. Blood Adv. 2021, 5, 2925–2934. [Google Scholar] [CrossRef] [PubMed]
- Hijiya, N.; Millot, F.; Suttorp, M. Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions. Pediatr. Clin. N. Am. 2015, 62, 107–119. [Google Scholar] [CrossRef] [PubMed]
- Millot, F.; Traore, P.; Guilhot, J.; Nelken, B.; Leblanc, T.; Leverger, G.; Plantaz, D.; Bertrand, Y.; Bordigoni, P.; Guilhot, F. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005, 116, 140–143. [Google Scholar] [CrossRef]
- Millot, F.; Suttorp, M.; Guilhot, J.; Sedlacek, P.; De Bont, E.S.; Li, C.K.; Kalwak, K.; Lausen, B.; Culic, S.; Dresse, M.F.; et al. The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and preliminary results. Blood 2012, 120, 3741. [Google Scholar] [CrossRef]
- Kalmanti, L.; Saussele, S.; Lauseker, M.; Proetel, U.; Müller, M.C.; Hanfstein, B.; Schreiber, A.; Fabarius, A.; Pfirrmann, M.; Schnittger, S.; et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: Results from the randomized CML study IV. Ann. Hematol. 2014, 93, 71–80. [Google Scholar] [CrossRef] [Green Version]
- Krumbholz, M.; Karl, M.; Tauer, J.T.; Thiede, C.; Rascher, W.; Suttorp, M.; Metzler, M. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer 2012, 51, 1045–1053. [Google Scholar] [CrossRef]
- Meissner, R.V.; Dias, P.M.; Covas, D.T.; Job, F.; Leite, M.; Nardi, N.B. A polymorphism in exon b2 of the major breakpoint cluster region (M-bcr) identified in chronic myeloid leukaemia patients. Br. J. Haematol. 1998, 103, 224–226. [Google Scholar] [CrossRef]
- Branford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.P.; Hughes, T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99, 3472–3475. [Google Scholar] [CrossRef]
- Schmidt, M.; Rinke, J.; Schäfer, V.; Schnittger, S.; Kohlmann, A.; Obstfelder, E.; Kunert, C.; Ziermann, J.; Winkelmann, N.; Eigendorff, E.; et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 2014, 28, 2292–2299. [Google Scholar] [CrossRef]
- Ernst, T.; Busch, M.; Rinke, J.; Ernst, J.; Haferlach, C.; Beck, J.F.; Hochhaus, A.; Gruhn, B. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia 2018, 32, 2046–2049. [Google Scholar] [CrossRef] [PubMed]
- Youn, M.; Smith, S.M.; Lee, A.G.; Chae, H.D.; Spiteri, E.; Erdmann, J.; Galperin, I.; Jones, L.M.; Donato, M.; Abidi, P.; et al. Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers 2021, 13, 6263. [Google Scholar] [CrossRef] [PubMed]
- Radivoyevitch, T.; Hlatky, L.; Landaw, J.; Sachs, R.K. Quantitative modeling of chronic myeloid leukemia: Insights from radiobiology. Blood 2012, 119, 4363–4371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Millot, F.; Maledon, N.; Guilhot, J.; Güneş, A.M.; Kalwak, K.; Suttorp, M. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur. J. Cancer 2019, 115, 17–23. [Google Scholar] [CrossRef]
- Adler, R.; Viehmann, S.; Kuhlisch, E.; Martiniak, Y.; Röttgers, S.; Harbott, J.; Suttorp, M. Correlation of BCR/ABL transcript variants with patients’ characteristics in childhood chronic myeloid leukaemia. Eur. J. Haematol. 2009, 82, 112–118. [Google Scholar] [CrossRef]
- Castagnetti, M.; Sainati, L.; Giona, F.; Varotto, S.; Carli, M.; Rigamonti, W. Conservative management of priapism secondary to leukemia. Pediatr. Blood Cancer 2008, 51, 420–423. [Google Scholar] [CrossRef]
- Kurosawa, H.; Tanizawa, A.; Tono, C.; Watanabe, A.; Shima, H.; Ito, M.; Yuza, Y.; Hotta, N.; Muramatsu, H.; Okada, M.; et al. Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr. Blood Cancer 2016, 63, 406–411. [Google Scholar] [CrossRef]
- Sokal, J.E.; Cox, E.B.; Baccarani, M.; Tura, S.; Gomez, G.A.; Robertson, J.E.; Tso, C.Y.; Braun, T.J.; Clarkson, B.D.; Cervantes, F. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984, 63, 789–799. [Google Scholar] [CrossRef] [Green Version]
- Hasford, J.; Pfirrmann, M.; Hehlmann, R.; Allan, N.C.; Baccarani, M.; Kluin-Nelemans, J.C.; Alimena, G.; Steegmann, J.L.; Ansari, H.J. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Natl. Cancer Inst. 1998, 90, 850–858. [Google Scholar] [CrossRef] [Green Version]
- Hasford, J.; Baccarani, M.; Hoffmann, V.; Guilhot, J.; Saussele, S.; Rosti, G.; Guilhot, F.; Porkka, K.; Ossenkoppele, G.; Lindoerfer, D.; et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score. Blood 2011, 118, 686–692. [Google Scholar] [CrossRef]
- Gurrea Salas, D.; Glauche, I.; Tauer, J.T.; Thiede, C.; Suttorp, M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann. Hematol. 2015, 94, 1363–1371. [Google Scholar] [CrossRef] [PubMed]
- Pfirrmann, M.; Baccarani, M.; Saussele, S.; Guilhot, J.; Cervantes, F.; Ossenkoppele, G.; Hoffmann, V.S.; Castagnetti, F.; Hasford, J.; Hehlmann, R.; et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016, 30, 48–56. [Google Scholar] [CrossRef] [PubMed]
- Geelen, I.G.P.; Sandin, F.; Thielen, N.; Janssen, J.J.W.M.; Hoogendoorn, M.; Visser, O.; Cornelissen, J.J.; Hoglund, M.; Westerweel, P.E. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients. Leukemia 2018, 32, 2299–2303. [Google Scholar] [CrossRef] [PubMed]
- Millot, F.; Guilhot, J.; Suttorp, M.; Güneş, A.M.; Sedlacek, P.; De Bont, E.; Li, C.K.; Kalwak, K.; Lausen, B.; Culic, S.; et al. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica 2017, 102, 1704–1708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baccarani, M.; Saglio, G.; Goldman, J.; Hochhaus, A.; Simonsson, B.; Appelbaum, F.; Apperley, J.; Cervantes, F.; Cortes, J.; Deininger, M.; et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108, 1809–2039. [Google Scholar] [CrossRef] [Green Version]
- Baccarani, M.; Castagnetti, F.; Gugliotta, G.; Rosti, G. A review of the European LeukemiaNet recommendations for the management of CML. Ann. Hematol. 2015, 94 (Suppl. S2), S141–S147. [Google Scholar] [CrossRef] [PubMed]
- de la Fuente, J.; Baruchel, A.; Biondi, A.; de Bont, E.; Dresse, M.F.; Suttorp, M.; Millot, F.; International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee. Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years. Br. J. Haematol. 2014, 167, 33–47. [Google Scholar] [CrossRef]
- Giona, F.; Saglio, G.; Santopietro, M.; Menna, G.; Putti, M.C.; Micalizzi, C.; Iaria, G.; Santoro, N.; Ladogana, S.; Mura, R.; et al. Managing Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. The Italian Experience. EHA. In Proceedings of the 21st Congress of the European Hematology Association Copenhagen, The Italian Experience. EHA. Copenhagen, Denmark, 9–12 June 2016; p. 236. [Google Scholar]
- Neelakantan, P.; Gerrard, G.; Lucas, C.; Milojkovic, D.; May, P.; Wang, L.; Paliompeis, C.; Bua, M.; Reid, A.; Rezvani, K.; et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: Implications for early intervention strategies. Blood 2013, 121, 2739–2742. [Google Scholar] [CrossRef]
- Hanfstein, B.; Müller, M.C.; Hehlmann, R.; Erben, P.; Lauseker, M.; Fabarius, A.; Schnittger, S.; Haferlach, C.; Göhring, G.; Proetel, U.; et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26, 2096–2102. [Google Scholar] [CrossRef] [Green Version]
- Hughes, T.P.; Saglio, G.; Kantarjian, H.M.; Guilhot, F.; Niederwieser, D.; Rosti, G.; Nakaseko, C.; De Souza, C.A.; Kalaycio, M.E.; Meier, S.; et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014, 123, 1353–1360. [Google Scholar] [CrossRef] [Green Version]
- Branford, S.; Yeung, D.T.; Parker, W.T.; Roberts, N.D.; Purins, L.; Braley, J.A.; Altamura, H.K.; Yeoman, A.L.; Georgievski, J.; Jamison, B.A.; et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014, 124, 511–518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanfstein, B.; Shlyakhto, V.; Lauseker, M.; Hehlmann, R.; Saussele, S.; Dietz, C.; Erben, P.; Fabarius, A.; Proetel, U.; Schnittger, S.; et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014, 28, 1988–1992. [Google Scholar] [CrossRef] [PubMed]
- Deininger, M.W.; Kopecky, K.J.; Radich, J.P.; Kamel-Reid, S.; Stock, W.; Paietta, E.; Emanuel, P.D.; Tallman, M.; Wadleigh, M.; Larson, R.A.; et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br. J. Haematol. 2014, 164, 223–232. [Google Scholar] [CrossRef] [PubMed]
- Cortes, J.E.; Baccarani, M.; Guilhot, F.; Druker, B.J.; Branford, S.; Kim, D.W.; Pane, F.; Pasquini, R.; Goldberg, S.L.; Kalaycio, M.; et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 2010, 28, 424–430. [Google Scholar]
- Hehlmann, R.; Lauseker, M.; Jung-Munkwitz, S.; Leitner, A.; Müller, M.C.; Pletsch, N.; Proetel, U.; Haferlach, C.; Schlegelberger, B.; Balleisen, L.; et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J. Clin. Oncol. 2011, 29, 1634–1642. [Google Scholar] [CrossRef]
- Jain, P.; Kantarjian, H.; Nazha, A.; O’Brien, S.; Jabbour, E.; Romo, C.G.; Pierce, S.; Cardenas-Turanzas, M.; Verstovsek, S.; Borthakur, G.; et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: Results with four tyrosine kinase inhibitor modalities. Blood 2013, 121, 4867–4874. [Google Scholar] [CrossRef]
- Millot, F.; Guilhot, J.; Baruchel, A.; Petit, A.; Bertrand, Y.; Mazingue, F.; Lutz, P.; Vérité, C.; Berthou, C.; Galambrun, C.; et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood 2014, 124, 2408–2410. [Google Scholar] [CrossRef] [Green Version]
- Shao, H.; Zeng, Z.; Cen, J.; Zhang, J.; Bai, S.; Wu, C.; Gong, Y.; Wang, Y.; Qiu, H.; Chen, S.; et al. The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: A single-center study from China. Leuk Lymphoma 2018, 59, 2152–2158. [Google Scholar] [CrossRef]
- Giona, F.; Saglio, G.; Santopietro, M.; Menna, G.; Putti, M.C.; Micalizzi, C.; Iaria, G.; Santoro, N.; Ladogana, S.; Mura, R.; et al. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. Br. J. Haematol. 2016, 180, 895–898. [Google Scholar] [CrossRef] [Green Version]
- Rossoff, J.; Huynh, V.; Rau, R.E.; Macy, M.E.; Sulis, M.L.; Schultz, K.R.; Burke, M.J.; Athale, U.; O’Brien, M.M.; Gregory, J.J., Jr.; et al. Experience with ponatinib in paediatric patients with leukaemia. Br. J. Haematol. 2020, 189, 363–368. [Google Scholar] [CrossRef]
- Millot, F.; Suttorp, M.; Versluys, A.B.; Kalwak, K.; Nelken, B.; Ducassou, S.; Bertrand, Y.; Baruchel, A. ponatinib in childhood Philadelphia chromosome-positive leukemias: An international registry of childhood Chronic Myieloid Leukaemia Study. Eur. J. Cancer 2020, 136, 107–112. [Google Scholar] [CrossRef] [PubMed]
- Millot, F.; Brice, P.; Philippe, N.; Thyss, A.; Demeoq, F.; Wetterwald, M.; Boccara, J.F.; Vilque, J.P.; Guyotat, D.; Guilhot, J.; et al. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia. J. Pediatr. Hematol. Oncol. 2002, 24, 18–22. [Google Scholar] [CrossRef] [PubMed]
- Giona, F.; Moleti, M.L.; Giudice, I.D.; Testi, A.M.; Diverio, D.; De Cuia, M.R.; Mandelli, F.; Foa, R. Long-term Follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period. Br. J. Haematol. 2005, 130, 970–972. [Google Scholar] [CrossRef] [PubMed]
- Vener, C.; Banzi, R.; Ambrogi, F.; Ferrero, A.; Saglio, G.; Pravettoni, G.; Sant, M. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: A systematic review and meta-analysis. Blood Adv. 2020, 4, 2723–2735. [Google Scholar] [CrossRef] [PubMed]
- Hijiya, N.; Maschan, A.; Rizzari, C.; Shimada, H.; Dufour, C.; Goto, H.; Kang, H.J.; Guinipero, T.; Karakas, T.; Bautista, F.; et al. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia. Blood 2019, 134, 2036–2045. [Google Scholar] [CrossRef]
- Mariani, S.; Giona, F.; Basciani, S.; Brama, M.; Gnessi, L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008, 372, 111–112. [Google Scholar] [CrossRef]
- Tauer, J.T.; Nowasz, C.; Sedlacek, P.; de Bont, E.S.J.M.; Aleinikova, O.V.; Suttorp, M. Impairment of longitudinal growth by tyrosine kinase inhibitor (TKI) treatment—Data from a large pediatric cohort with chronic myeloid leukemia (CML). Blood 2014, 124, 522. [Google Scholar] [CrossRef]
- Patterson, B.; Samis, J.; Gore, L.; Zwaan, C.M.; Sacchi, M.; Sy, O.; Hijiya, N. Growth rate and endocrine effects of dasatinib therapy observed in a retrospective analysis of a phase 2 clinical trial for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). HemaSphere 2019, 3, 161. [Google Scholar] [CrossRef]
- Giona, F.; Malaspina, F.; Putti, M.C.; Ladogana, S.; Mura, R.; Burnelli, R.; Vacca, N.; Rizzo, L.; Bianchi, S.; Moleti, M.L.; et al. Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. Br. J. Haematol. 2020, 188, e101–e105. [Google Scholar] [CrossRef]
- Walia, R.; Aggarwal, A.; Bhansali, A.; Aggarwal, A.; Varma, N.; Sachdeva, N.; Khandelwal, N.; Bansal, D. Acquired neuro-secretory defect in growth hormone secretion due to Imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia. Pediatr. Hematol. Oncol. 2020, 37, 99–108. [Google Scholar] [CrossRef]
- Rousselot, P.; Charbonnier, A.; Cony-Makhoul, P.; Agape, P.; Nicolini, F.E.; Varet, B.; Gardembas, M.; Etienne, G.; Rea, D.; Roy, L.; et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J. Clin. Oncol. 2014, 32, 424–430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Etienne, G.; Guilhot, J.; Rea, D.; Rigal-Huguet, F.; Nicolini, F.; Charbonnier, A.; Guerci-Bresler, A.; Legros, L.; Varet, B.; Gardembas, M.; et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J. Clin. Oncol. 2017, 35, 298–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rea, D.; Nicolini, F.E.; Tulliez, M.; Guilhot, F.; Guilhot, J.; GuerciBresler, A.; Gardembas, M.; Coiteux, V.; Guillerm, G.; Legros, L.; et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study. Blood 2017, 129, 846–854. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hochhaus, A.; Masszi, T.; Giles, F.J.; Radich, J.P.; Ross, D.M.; Gomez Casares, M.T.; Hellmann, A.; Stentoft, J.; Conneally, E.; García-Gutiérrez, V.; et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study. Leukemia 2017, 31, 1525–1531. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saussele, S.; Richter, J.; Guilhot, J.; Gruber, F.X.; Hjorth-Hansen, H.; Almeida, A.; Janssen, J.J.W.M.; Mayer, P.J.; Koskenvesa, P.; Panayiotidis, P.; et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, nonrandomised, trial. Lancet Oncol. 2018, 19, 747–757. [Google Scholar] [CrossRef] [Green Version]
- Hochhaus, A.; Baccarani, M.; Silver, R.T.; Schiffer, C.; Apperley, J.F.; Cervantes, F.; Clark, R.E.; Cortes, J.E.; Deininger, M.W.; Guilhot, F.; et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020, 34, 966–984. [Google Scholar] [CrossRef] [Green Version]
- Millot, F.; Claviez, A.; Leverger, G.; Corbaciglu, S.; Groll, A.H.; Suttorp, M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatr. Blood Cancer 2014, 61, 355–357. [Google Scholar] [CrossRef]
- de Bruijn, C.M.A.; Millot, F.; Suttorp, M.; Borisevich, M.; Brons, P.; Lausen, B.; de Bont, E.S.J.M. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: Results of the STOP IMAPED study. Br. J. Haematol. 2019, 185, 718–724. [Google Scholar] [CrossRef]
- Flygt, H.; Sandin, F.; Dahlén, T.; Dremaine, A.; Lübking, A.; Markevärn, B.; Myhr-Eriksson, C.; Olsson, K.; Olsson-Strömberg, U.; Själander, A.; et al. Successful tyrosine kinase inhibitor discontinuation outside clinical trials—Data from the population-based Swedish chronic myeloid leukaemia registry. Br. J. Haematol. 2021, 193, 915–921. [Google Scholar] [CrossRef]
- Andolina, J.R.; Burke, M.J.; Hijiya, N.; Chaudhury, S.; Schultz, K.R.; Roth, M.E. Practice patterns of physician treatment for pediatric chronic myelogenous leukemia. Biol. Blood Marrow Transpl. 2019, 25, 321–327. [Google Scholar] [CrossRef] [Green Version]
- Cwynarski, K.; Roberts, I.A.; Iacobelli, S.; Van Biezen, A.; Brand, R.; Devergie, A.; Vossen, J.M.; Aljurf, M.; Arcese, W.; Locatelli, F.; et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003, 102, 1224–1231. [Google Scholar] [CrossRef] [PubMed]
- Suttorp, M.; Yaniv, I.; Schultz, K.R. Controversies in the treatment of CML in children and adolescents: TKI versus BMT? Biol. Blood Marrow Transpl. 2011, 17 (Suppl. S1), S115–S122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muramatsu, H.; Kojima, S.; Yoshimi, A.; Atsuta, Y.; Kato, K.; Nagatoshi, Y.; Inoue, M.; Koike, K.; Kawase, T.; Ito, M.; et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Biol. Blood Marrow Transpl. 2010, 16, 231–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chaudhury, S.; Sparapani, R.; Hu, Z.H.; Nishihori, T.; Abdel-Azim, H.; Malone, A.; Olsson, R.; Hamadani, M.; Daly, A.; Bacher, U.; et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol. Blood Marrow Transpl. 2016, 22, 1056–1064. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suttorp, M.; Claviez, A.; Bader, P.; Peters, C.; Gadner, H.; Ebell, W.; Dilloo, D.; Kremens, B.; Kabisch, H.; Führer, M.; et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: Results from the prospective trial CML-paed I. Klin. Padiatr. 2009, 221, 351–357. [Google Scholar] [CrossRef] [PubMed]
- Ruiz-Argüelles, G.J.; Tarin-Arzaga, L.C.; Gonzalez-Carrillo, M.L.; Gutierrez-Riveroll, K.I.; Rangel-Malo, R.; Gutiérrez-Aguirre, C.H.; Cantú-Rodríguez, O.G.; Gómez-Almaguer, D.; Giralt, S. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transpl. 2008, 42, 23–28. [Google Scholar] [CrossRef] [Green Version]
- Hafez, H.A.; Abdallah, A.; Hammad, M.; Hamdy, N.; Yassin, D.; Salem, S.; Hassanain, O.; Elhalaby, L.; Elhaddad, A. Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single-center experience. Pediatr. Transpl. 2020, 24, e13664. [Google Scholar] [CrossRef]
- Gómez-Almaguer, D.; Cantú-Rodríguez, O.G.; Gutiérrez-Aguirre, C.H.; Ruiz-Argüelles, G.J. The treatment of CML at an environment with limited resources. Hematology 2016, 21, 576–582. [Google Scholar] [CrossRef] [Green Version]
- Ohanian, M.; Kantarjian, H.M.; Quintas-Cardama, A.; Jabbour, E.; Abruzzo, L.; Verstovsek, S.; Borthakur, G.; Ravandiet, F.; Garcia-Manero, G.; Champlin, R.; et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin. Lymphoma Myeloma Leuk. 2014, 14, 155–162.e1. [Google Scholar] [CrossRef] [Green Version]
- Geelen, I.G.P.; Thielen, N.; Janssen, J.J.W.M.; Hoogendoorn, M.; Roosma, T.J.A.; Willemsen, S.P. Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia. Haematologica 2017, 102, 1842. [Google Scholar] [CrossRef]
- Jain, P.; Kantarjian, H.M.; Ghorab, A.; Sasaki, K.; Jabbour, E.J.; Nogueras Gonzalez, G. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 2017, 1235, 4391–4402. [Google Scholar] [CrossRef] [PubMed]
References | Number Patients | Type of TKI | Dose/Daily | CCyR (Time) (%) | Time to CCyR | MMR (Time) (%) | Time to MMR | EFS/PFS/OS Probability | Median Follow-Up |
---|---|---|---|---|---|---|---|---|---|
Champagne MA et al., 2011 [4] | 51 | Imatinib | 340 mg/m2 | 72% | 5.6 mo | 27% | NR | 3-yrs PFS 72 ± 6.4% 3-yrs OS 92 ± 3.9% | 3.8 years |
Millot F et al., 2011 [3] | 44 | Imatinib | 260 mg/m2 | 12 mo: 61% Overall: 77% | NR | 12 mo: 31% Overall: 57% | NR | 3-year PFS 98% | 31 months |
Giona F et al., 2015 [5] | 47 | Imatinib | 340 mg/m2 | 6 mo: 93% 12-mo: 96% | 6.3 mo | 12 mo: MMR 66% 24 mo: MMR 83% Deep MR: 33% | 15 months (BCR-ABL1 ≤ 0.01%) | 10-yrs PFS: 60% 10-yrs OS: 100% | 52 months |
Suttorp M et al., 2018 [6] | 140 | Imatinib | 273 mg/m2 | 12 mo: 63% | NR | 18 mo: 59% | NR | 18-mo EFS: 97% 18-mo OS: 100% | 25 months |
Gore L et al., 2018 [12] | 84 | Dasatinib | 60 mg/m2 (tablet) 72 mg/m2 (PFOS) | 6 mo: 55% | 5.6 mo | 12 mo: MMR 52% 24 mo: MMR 70% | 8.9 mo | 4-yrs PFR: 94% 4-yrs PFR: 94% | 24 months |
Hijiya N et al., 2019 [13] | 25 | Nilotinib | 230 mg/m2 twice daily | 12 mo: 64% 24 mo: 84% | 5.6 mo | 12 mo: 64% 24 mo: 68% | 5.6 mo | 2-yrs EFS: 91.2% | 22 months |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Giona, F.; Bianchi, S. Update in Childhood Chronic Myeloid Leukemia. Hemato 2022, 3, 718-730. https://doi.org/10.3390/hemato3040048
Giona F, Bianchi S. Update in Childhood Chronic Myeloid Leukemia. Hemato. 2022; 3(4):718-730. https://doi.org/10.3390/hemato3040048
Chicago/Turabian StyleGiona, Fiorina, and Simona Bianchi. 2022. "Update in Childhood Chronic Myeloid Leukemia" Hemato 3, no. 4: 718-730. https://doi.org/10.3390/hemato3040048